B. Han

B. Han, Yu Dong, Xueyan Zhang, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MicroRNA-107-5p suppresses non-small cell lung cancer by directly targeting oncogene epidermal growth factor receptor

B. Han, ping wang, Huimin Wang, 2017, Oncotarget.

EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study.

B. Han, N. Normanno, R. McCormack, 2017, Lung cancer.

Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?

B. Han, R. Ferris, A. Lokshin, 2006, Cancer and Metastasis Reviews.

Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population

Hongbing Shen, C. Amos, W. Tan, 2012, Nature Genetics.

Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer

J. Wu, C. Bai, B. Han, 2017, Scientific Reports.

Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis.

B. Han, P. Gu, Wei Zhang, 2009, European journal of cancer.

Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel.

B. Han, K. Gu, Midie Xu, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

The Value of Tumor Markers in Evaluating Chemotherapy Response and Prognosis in Chinese Patients with Advanced Non-Small Cell Lung Cancer

B. Han, Bo Jin, Ai-mi Huang, 2010, Chemotherapy.

Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells

Y. Li, B. Han, Weifeng Mao, 2017, Yonsei medical journal.

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer

Ying Cheng, B. Han, He-long Zhang, 2016, BMC Cancer.

A pharmacogenetics study of platinum-based chemotherapy in lung cancer: ABCG2 polymorphism and its genetic interaction with SLC31A1 are associated with response and survival

C. Bai, B. Han, Haijian Wang, 2021, Journal of Cancer.

Influence of single nucleotide polymorphisms in ABCB 1 , ABCG 2 and ABCC 2 on clinical outcomes to paclitaxel-platinum chemotherapy in patients with non-small-cell lung cancer

B. Han, D. Lu, Wenting Wu, 2016 .

Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial

Ying Cheng, B. Han, K. Nan, 2021, Thoracic cancer.

A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab

B. Han, K. Gu, Midie Xu, 2020, Oncoimmunology.

Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies

B. Han, Yu Dong, H. Zhong, 2020, International journal of cancer.

The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus

B. Han, Lin Wang, Jun Lu, 2021, Frontiers in Oncology.

Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas

B. Han, Jun Lu, R. Qiao, 2018, Cancer.

Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients

B. Han, Liyan Jiang, Y. Lou, 2015, Medical Oncology.

Advances in Lung Cancer and Treatment Research

B. Han, Xiaofei Wang, 2013 .

[The Mechanism of Resistance to EGFR-TKI in NSCLC and Exploration to Overcome the Resistance.].

B. Han, J. Pei, 2009, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer

B. Han, Yu Dong, Hai Hu, 2021, Frontiers in Oncology.

Expression Level of Wnt5a Was Related to the Therapeutic Effects of First-Generation EGFR-TKIs

B. Han, Xueyan Zhang, H. Zhong, 2020, OncoTargets and therapy.

Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study

B. Han, Qingqing Zhu, Jie Liu, 2020, International Journal of Clinical Oncology.

Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11).

Ying Cheng, B. Han, Baolan Li, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis

B. Han, Shu-yuan Wang, Wei Zhang, 2020, Targeted Oncology.

The Advent of Ultra-high Volume Thoracic Surgical Centers in Shanghai

A. Sihoe, B. Han, G. Jiang, 2017, World Journal of Surgery.

不同剂量紫杉醇联合卡铂一线治疗晚期非小细胞肺癌的临床研究

B. Han, H. Bai, Jie Shen, 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.

B. Han, Bo Jin, Xueyan Zhang, 2016, Lung cancer.

EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study.

B. Han, Y. Lou, Jianlin Xu, 2020, Clinical lung cancer.

Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.

B. Han, Yu Dong, Shu-yuan Wang, 2020, Clinical lung cancer.

Different characteristics and survival in non‐small cell lung cancer patients with primary and acquired EGFR T790M mutation

B. Han, Yu Dong, Jun Lu, 2019, International journal of cancer.

Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.

Ying Cheng, Yi-long Wu, B. Han, 2019, Lung cancer.

Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib

B. Han, R. Qiao, Jianlin Xu, 2019, Targeted Oncology.

Accuracy and clinical influence of plasma EGFR mutation detection in management of advanced lung adenocarcinoma.

B. Han, C. Shi, J. Qian, 2017, International journal of clinical and experimental pathology.

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China

B. Han, Bo Jin, Xueyan Zhang, 2016, Journal of Cancer Research and Clinical Oncology.

Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC.

B. Han, Huimin Wang, L. Xiong, 2012, Oncology letters.

Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?

B. Han, Xueyan Zhang, Huimin Wang, 2018, Lung cancer.

Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS in advanced non-small cell lung cancer.

B. Han, H. Zhong, C. Shi, 2016, Gene.

Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma

B. Han, Bo Jin, Yu Dong, 2014, Tumor Biology.

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

B. Han, S. Novello, N. Normanno, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer

B. Han, L. Xiong, H. Bai, 2017, OncoTargets and therapy.

EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

B. Han, Bo Jin, Xueyan Zhang, 2016, Scientific Reports.

Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

B. Han, Bo Jin, Xueyan Zhang, 2016, Scientific Reports.

Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (INFORM; C-TONG 0804)

Ying Cheng, B. Han, Yunpeng Liu, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

厄洛替尼100 mg/天治疗化疗后进展的晚期肺腺癌的临床研究

B. Han, L. Xiong, Jie Shen, 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma

B. Han, Jianlin Xu, Shu-yuan Wang, 2019, Molecular Diagnosis & Therapy.

Combination of chemotherapy and gefitinib as first‐line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial

B. Han, Bo Jin, Yu Dong, 2017, International journal of cancer.

China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version)

D. Lin, B. Han, Changli Wang, 2017, Asia-Pacific journal of clinical oncology.

中国埃克替尼治疗非小细胞肺癌专家共识（2016年版）

B. Han, Jianxing He, Y. Ling, 2016, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version).

B. Han, C. Bai, Jianxing He, 2015, Journal of Thoracic Disease.

China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version).

B. Han, C. Bai, Jianxing He, 2015, Journal of thoracic disease.

中国埃克替尼治疗非小细胞肺癌专家共识(2015版)

B. Han, Jianxing He, Y. Ling, 2015, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).

B. Han, Yiping Zhang, Shucai Zhang, 2014, Lung cancer.

Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma

B. Han, Bo Jin, Yu Dong, 2014, Acta Pharmacologica Sinica.

Ⅳ期肺腺癌二线EGFR-TKIs治疗失败后预后因素分析

B. Han, Liyan Jiang, Lin Wang, 2013, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China

T. Mok, Yi-long Wu, D. Chu, 2012, Asia-Pacific journal of clinical oncology.

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.

Ying Cheng, B. Han, Yunpeng Liu, 2012, The Lancet. Oncology.

Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy

Xifeng Wu, J. Roth, Y. Ye, 2017, Carcinogenesis.

MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma

B. Han, Xueyan Zhang, Huimin Wang, 2016, Oncotarget.

Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients

J. Wu, C. Bai, B. Han, 2015, PloS one.

Association of CASP3 polymorphism with hematologic toxicity in patients with advanced non‐small‐cell lung carcinoma treated with platinum‐based chemotherapy

B. Han, Yi Xie, Hongyan Chen, 2012, Cancer science.

Epithelial neoplasia coincides with exacerbated injury and fibrotic response in the lungs of Gprc5a-knockout mice following silica exposure

B. Han, B. Zhou, Jiong Deng, 2015, Oncotarget.

Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis.

B. Han, Z. Wang, Li-jun Ma, 2015, Molecular and clinical oncology.

Current small cell lung cancer treatment in China

B. Han, Chengping Hu, P. Xing, 2015, Thoracic cancer.

Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer

C. Bai, B. Han, Qiang Li, 2018, Investigational New Drugs.

Low-Dose Paclitaxel Prior to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer Growth

B. Han, A. Lokshin, G. Shurin, 2007, Clinical Cancer Research.

Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study

B. Han, Xueyan Zhang, Huimin Wang, 2020, Targeted Oncology.

Association of POLK Polymorphisms with Platinum-Based Chemotherapy Response and Severe Toxicity in Non-small Cell Lung Cancer Patients

B. Han, D. Lu, Bo Jin, 2014, Cell Biochemistry and Biophysics.

Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy

G. Jin, B. Han, X. Song, 2015, The Pharmacogenomics Journal.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer

Yang Zhang, C. Bai, B. Han, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer.

B. Han, Changli Wang, J. Rigas, 2013, Journal of thoracic disease.

Ⅰ期非小细胞肺癌术后预后的多因素分析

B. Han, A. Gu, Jie Zhang, 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Treatment of pulmonary epithelioid hemangioendothelioma with combination chemotherapy: Report of three cases and review of the literature

B. Han, B. Ye, Wang Li, 2013, Oncology letters.

Capture‐Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA‐Releasing Capability in Advanced Lung Cancer

B. Han, S. Chuai, Liyan Jiang, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Establishment and management of a lung cancer biobank in Eastern China

B. Han, Jie Zhang, Keke Yu, 2015, Thoracic cancer.

New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer

B. Han, Jianlin Xu, Yanwei Zhang, 2020, Journal of Cancer Research and Clinical Oncology.

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

Ying Cheng, Yi-long Wu, B. Han, 2017, ESMO Open.

Matrix metalloproteinase‐2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first‐line, platinum‐based chemotherapy

J. Wu, C. Bai, B. Han, 2012, Cancer.

Lung cancer and benign lung diseases in patients with serious vitamin D deficiency in eastern China

Jing Wu, B. Han, L. Xiong, 2012, Thoracic cancer.

Clinical Features and Outcomes Analysis of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy

B. Han, Xueyan Zhang, Jianlin Xu, 2020, Frontiers in Oncology.

Learning curve of electromagnetic navigation bronchoscopy for diagnosing peripheral pulmonary nodules in a single institution

B. Han, Jiayuan Sun, Lei Zhu, 2017 .

Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients.

B. Han, Xueyan Zhang, W. Nie, 2019, Lung cancer.

中国非小细胞肺癌免疫检查点抑制剂治疗专家共识（2020年版）

Jingjing Liu, Ying Cheng, B. Han, 2021, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non‐small‐cell lung cancer patients with EGFR mutations

B. Han, Bo Jin, Xueyan Zhang, 2017, International journal of cancer.

CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients

B. Han, Xueyan Zhang, Huimin Wang, 2020, Frontiers in Oncology.

Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NCSLC).

Ying Cheng, Yi-long Wu, B. Han, 2019, Journal of Clinical Oncology.

OCT4&SOX2‐specific cytotoxic T lymphocytes plus programmed cell death protein 1 inhibitor presented with synergistic effect on killing lung cancer stem‐like cells in vitro and treating drug‐resistant lung cancer mice in vivo

B. Han, Xueyan Zhang, Huimin Wang, 2018, Journal of cellular physiology.

Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial

Ying Cheng, C. Bai, B. Han, 2013, Supportive Care in Cancer.

VCP gene variation predicts outcome of advanced non-small-cell lung cancer platinum-based chemotherapy

C. Bai, B. Han, W. Wu, 2013, Tumor Biology.

Endobronchial ultrasound-guided transbronchial needle aspiration in diagnosing intrathoracic tuberculosis.

B. Han, D. Garfield, Jiayuan Sun, 2013, The Annals of thoracic surgery.

Utility of endobronchial ultrasound‐guided transbronchial needle aspiration in diagnosing non‐specific inflammatory intrathorcacic lymphadenitis

B. Han, Jiayuan Sun, Huizhen Yang, 2018, The clinical respiratory journal.

Endobronchial Ultrasound Elastography for Evaluation of Intrathoracic Lymph Nodes: A Pilot Study

B. Han, F. Herth, Jiayuan Sun, 2017, Respiration.

Determining factors in diagnosing pulmonary sarcoidosis by endobronchial ultrasound-guided transbronchial needle aspiration.

B. Han, D. Garfield, Jiayuan Sun, 2015, The Annals of thoracic surgery.

First 30 endobronchial ultrasound-guided transbronchial needle aspirations: a single institution's early experience.

B. Han, Xiangteng Wang, Jiayuan Sun, 2011, Chinese medical journal.

Role of endobronchial ultrasound‐guided transbronchial needle aspiration in the diagnosis of bronchogenic carcinoma: Experience of a single institution in China

B. Han, Jiayuan Sun, Jie Shen, 2010, Thoracic cancer.

RAD18 polymorphisms are associated with platinum-based chemotherapy toxicity in Chinese patients with non-small cell lung cancer

B. Han, Rong Li, Jun-yi Ye, 2016, Acta Pharmacologica Sinica.

Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.

B. Han, Hongyan Chen, D. Lu, 2014, Clinical lung cancer.

Vitamin D inhibition of lung adenocarcinoma cell proliferation in vitro

B. Han, Rong Li, Y. Lou, 2014, Tumor Biology.

FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor.

B. Han, R. Qiao, Jianlin Xu, 2021, Life sciences.

A Classification Method Based on Principal Components of SELDI Spectra to Diagnose of Lung Adenocarcinoma

Li Jin, Feng Yao, Qianqian Peng, 2012, PloS one.

Chinese experts’ consensus on the Internet of Things-aided diagnosis and treatment of coronavirus disease 2019 (COVID-19)

Jian Zhou, Tao Xu, Min Zhang, 2020, Clinical eHealth.

[Preoperative induction chemotherapy for resectable stage IIIA non-small-cell lung cancer: a meta-analysis of 13 double-blind, randomized clinical trials.].

B. Han, Yu Dong, Liyan Jiang, 2008, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

代谢组学方法分析肺癌患者血清和尿液小分子代谢产物的初步研究

B. Han, Liyan Jiang, Heng Zhao, 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of non-lymph node thoracic lesions

B. Han, D. Garfield, Jiayuan Sun, 2013, Annals of thoracic medicine.

Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery.

B. Han, Xueyan Zhang, H. Zhong, 2020, Lung cancer.

Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.

B. Han, R. Qiao, Jianlin Xu, 2019, Clinical lung cancer.

Pathologic subtype-defined prognosis is dependent on both tumor stage and status of oncogenic driver mutations in lung adenocarcinoma.

Y. Li, B. Han, Shichun Tu, 2017, Oncotarget.

Sonographic Features of Endobronchial Ultrasound in Differentiation of Benign Lymph Nodes.

Lei Wang, B. Han, Jiayuan Sun, 2016, Ultrasound in medicine & biology.

Chemotherapy-induced leukopenia as a prognostic factor in patients with metastatic non-small cell lung cancer treated with platinum-based chemotherapy

B. Han, Bo Jin, Ai-mi Huang, 2016 .

RGB and HSV quantitative analysis of autofluorescence bronchoscopy used for characterization and identification of bronchopulmonary cancer

B. Han, Yong Li, Jiayuan Sun, 2016, Cancer medicine.

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

Jing Zhu, Ying Cheng, B. Han, 2020, Cancer medicine.

Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial

B. Han, He-long Zhang, Yi Hu, 2021, Cancer biology & medicine.

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer

B. Han, Bo Jin, Xueyan Zhang, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[The Clinical Analysis of 21 Patients with Lymphoepithelioma-like Carcinoma after Operation.].

B. Han, Jinjing Xia, Liyan Jiang, 2009, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Navigation Bronchoscopy-Guided Radiofrequency Ablation for Nonsurgical Peripheral Pulmonary Tumors

B. Han, F. Herth, Jiayuan Sun, 2017, Respiration.

Clinical outcomes of patients with or without common AEs in anlotinib cohort: Subgroup analysis of the ALTER0303 trial.

Ying Cheng, B. Han, K. Nan, 2019, Journal of Clinical Oncology.

Tumour mutational burden in treatment-resistant tumours.

B. Han, H. Zhong, W. Nie, 2020, The Lancet. Oncology.

Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.

B. Han, H. Zhong, R. Zhong, 2021, International Immunopharmacology.

Quantification of Rare Circulating Tumor Cells in Non-Small Cell Lung Cancer by Ligand-Targeted PCR

B. Han, Guohua Yang, X. Liang, 2013, PloS one.

Role of miR-497 in VEGF-A-mediated cancer cell growth and invasion in non-small cell lung cancer.

B. Han, M. Yao, C. Shi, 2016, The international journal of biochemistry & cell biology.

[The clinical analysis of first-line palitaxel plus platinum-based chemotherapy to treat elderly non-small cell lung cancer.].

B. Han, Jie Shen, T. Chu, 2009, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Clinical features of three avian influenza H7N9 virus‐infected patients in Shanghai

B. Han, Hong Chen, Wei Chen, 2014, The clinical respiratory journal.

Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer

B. Han, H. Zhong, R. Zhong, 2011, Cancer Immunology, Immunotherapy.

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

B. Han, Xueyan Zhang, H. Zhong, 2021, Respiratory Research.

Predicting the recurrence risk factors and clinical outcomes of peripheral pulmonary adenocarcinoma ≤3 cm with wedge resection

B. Han, Haiquan Chen, Difan Zheng, 2017, Journal of Cancer Research and Clinical Oncology.

Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma

B. Han, Xueyan Zhang, Y. Lou, 2019, Targeted Oncology.

Predictors of recurrence and survival of pathological T1N0M0 invasive adenocarcinoma following lobectomy

B. Han, Haiquan Chen, Difan Zheng, 2018, Journal of Cancer Research and Clinical Oncology.

The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China

B. Han, Bo Jin, Xueyan Zhang, 2016, OncoTargets and therapy.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer.

B. Han, Bo Jin, Xueyan Zhang, 2016, Clinical lung cancer.

Serum dickkopf-1 as a clinical and prognostic factor in non-small cell lung cancer patients with bone metastases.

B. Han, R. Qiao, T. Chu, 2017, Oncotarget.

Effectiveness of anlotinib in patients with small‐cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study

Y. Liu, Ying Cheng, B. Han, 2021, Thoracic cancer.

[Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of intrapulmonary lesions].

B. Han, Jiayuan Sun, Huizhen Yang, 2013, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

B. Han, K. Nan, F. Jin, 2018, Journal of Thoracic Oncology.

原发性肺癌诊疗规范(2011年版)

B. Han, Qinghua Zhou, Yilong Wu, 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Gprc5a-knockout mouse lung epithelial cells predicts ceruloplasmin, lipocalin 2 and periostin as potential biomarkers at early stages of lung tumorigenesis

B. Han, Pengfei Jiang, Jiong Deng, 2017, Oncotarget.

OA13.03 Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 Trial

Xia Li, Ying Cheng, B. Han, 2018, Journal of Thoracic Oncology.

Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery.

B. Han, Xueyan Zhang, H. Zhong, 2021, Lung cancer.

The evaluation of efficacy and safety of sunitinib on EGFR‐TKI pretreated advanced non‐small cell lung cancer patients in China

B. Han, Wei Zhu, Jiaqi Huang, 2014, The clinical respiratory journal.

Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells

B. Han, Xiaodong Zhao, W. Xu, 2019, BMC Medical Genomics.

Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review

B. Han, Xueyan Zhang, Jun Lu, 2018, Targeted Oncology.

B. Han, W. Nie, Bo Zhang, 2021, JAMA oncology.

A clinicopathological study of resected non-small cell lung cancers 2 cm or less in diameter: a prognostic assessment

B. Han, Jie Shen, C. Shi, 2011, Medical oncology.

Lung cancer-derived Dickkopf1 is associated with bone metastasis and the mechanism involves the inhibition of osteoblast differentiation.

B. Han, Liyan Jiang, H. Zhong, 2014, Biochemical and biophysical research communications.

MicroRNA-107-5p suppresses non-small cell lung cancer by directly targeting oncogene epidermal growth factor receptor

B. Han, ping wang, Huimin Wang, 2017, Oncotarget.

Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases

B. Han, R. Qiao, Y. Lou, 2019, Journal of Cardiothoracic Surgery.

Wnt signaling regulates the stemness of lung cancer stem cells and its inhibitors exert anticancer effect on lung cancer SPC-A1 cells

B. Han, Xueyan Zhang, Huimin Wang, 2015, Medical Oncology.

Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib

B. Han, H. Zhong, Jianlin Xu, 2019, Journal of Cancer Research and Clinical Oncology.

Electromagnetic navigation bronchoscopy guided injection of methylene blue combined with hookwire for preoperative localization of small pulmonary lesions in thoracoscopic surgery.

B. Han, Jiayuan Sun, X. Mao, 2015, Journal of thoracic disease.

The REACH Trial: A Randomized Controlled Trial Assessing the Safety and Effectiveness of the Spiration® Valve System in the Treatment of Severe Emphysema

C. Bai, F. Herth, B. Han, 2018, Respiration.

Genetic polymorphism of SLC31A1 is associated with clinical outcomes of platinum-based chemotherapy in non-small-cell lung cancer patients through modulating microRNA-mediated regulation

J. Wu, C. Bai, B. Han, 2018, Oncotarget.

Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma

B. Han, Haiquan Chen, Q. Luo, 2016, Journal of Cancer Research and Clinical Oncology.

DUBR suppresses migration and invasion of human lung adenocarcinoma cells via ZBTB11-mediated inhibition of oxidative phosphorylation

B. Han, Midie Xu, Jun Lu, 2021, Acta pharmacologica Sinica.

DUBR suppresses migration and invasion of human lung adenocarcinoma cells via ZBTB11-mediated inhibition of oxidative phosphorylation

B. Han, Midie Xu, Jun Lu, 2021, Acta Pharmacologica Sinica.

A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting

B. Han, Yun Feng, Ying Chen, 2014, Scientific Reports.

Immune cell infiltration features and related marker genes in lung cancer based on single-cell RNA-seq

B. Han, H. Zhong, R. Zhong, 2020, Clinical and Translational Oncology.

Development and validation of a predictive model for the diagnosis of solid solitary pulmonary nodules using data mining methods.

B. Han, Wen Gao, W. Fang, 2019, Journal of thoracic disease.

The Value of Autofluorescence Bronchoscopy Combined with White Light Bronchoscopy Compared with White Light Alone in the Diagnosis of Intraepithelial Neoplasia and Invasive Lung Cancer: A Meta-Analysis

Jiayuan Sun, B. Han, B. Lam, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

XPA gene rs1800975 single nucleotide polymorphism and lung cancer risk: a meta-analysis

B. Han, Xueyan Zhang, L. Xiong, 2014, Tumor Biology.

Going Beyond Results of the PEMBRO-RT Trial.

B. Han, Bo Zhang, 2019, JAMA oncology.

[Vascular endothelial growth factor inhibits dendritic cells from patients with non-small cell lung carcinoma].

B. Han, M. Liao, Q. Dong, 2003, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

P2.01-31 Preliminary Results of Second Generation ALK Inhibitor PLB1003: A Phase La Study

B. Han, J. Qian, T. Chu, 2019, Journal of Thoracic Oncology.

High‐resolution Computed Tomography Features Distinguishing Benign and Malignant Lesions Manifesting as Persistent Solitary Subsolid Nodules

B. Han, W. Fang, F. Qian, 2018, Clinical lung cancer.

First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).

B. Han, He-long Zhang, Yunpeng Liu, 2016 .

Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer.

B. Han, Sang-We Kim, Dae-Ho Lee, 2013, European journal of cancer.

M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC

B. Han, W. Ying, T. Chu, 2017, Clinical and Translational Oncology.

Does surgically resected small‐cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?

B. Han, Xueyan Zhang, H. Zhong, 2020, Thoracic cancer.

Risk factors of lymph node metastasis in patients with non‐small cell lung cancer ≤ 2 cm in size: A monocentric population‐based analysis

B. Han, C. Shi, Xiyan Yu, 2017, Thoracic cancer.

A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer.

B. Han, X. Zhang, Z. Chen, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Advanced detecting techniques of EGFR mutation for non-small cell lung cancer

B. Han, Liyan Jiang, Y. Niu, 2012 .

[Diagnostic value of bone metabolic markers ICTP and BAP in lung cancer patients with bone metastases].

B. Han, Y. Xin, J. Lou, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

The prognostic impact of hypoxia-inducible factor-1α and p-Akt expressions in gastric adenocarcinoma

B. Han, R. Xu, M. Qiu, 2008 .

Phase II clinical trial of XELOX as first line treatment for patients with unresectable or metastatic gastric cancer

B. Han, Fenghua Wang, R. Xu, 2007 .

Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer

C. Bai, B. Han, Hongyan Chen, 2017, Scientific Reports.

Joe Y. Chang, J. Minna, Xifeng Wu, 2016, PloS one.

中国晚期原发性肺癌诊治专家共识（2016年版）

D. Lin, B. Han, Changli Wang, 2016, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Erlotinib as neoadjuvant treatment in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation (NCT01217619, ESTERN).

B. Han, L. Xiong, Jiayuan Sun, 2012 .

P1.03-062 Lung Cancer Screening with Low-Dose CT in China: Study Design and Baseline Results from the First Round Screening Arm

B. Han, Bo Jin, Xueyan Zhang, 2017 .

Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer

B. Han, Jinjing Xia, L. Xiong, 2017, Oncotarget.

Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis

B. Han, Bo Jin, Y. Lou, 2015, PloS one.

Subgroup analysis of histology in ALTER0303: Anlotinib hydrochloride as 3rd line and further line treatment in refractory advanced NSCLC patients (pts).

Ying Cheng, B. Han, K. Nan, 2018 .

Molecular profiling identifies prognostic markers of stage IA lung adenocarcinoma

B. Han, Shichun Tu, Jie Zhang, 2017, Oncotarget.

The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer.

B. Han, R. Qiao, L. Xiong, 2019, Annals of translational medicine.

Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population

B. Han, Huimin Wang, W. Wei-min, 2011, Medical oncology.

EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung cancer

B. Han, B. Zhou, Jiong Deng, 2014, Molecular Cancer.

Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.

B. Han, Haijian Wang, Hongyan Chen, 2012, Chest.

Clinical significance of visceral pleural and lymphovascular invasion in surgically resected adenosquamous lung cancer.

B. Han, F. Qian, Ya Chen, 2020, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer

Ying Cheng, B. Han, He-long Zhang, 2016, BMC Cancer.

The REACH study, a randomized controlled trial assessing the safety and effectiveness of the Spiration Valve System endobronchial therapy for severe emphysema: 12 month follow-up results

C. Bai, B. Han, N. Zhong, 2017 .

Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells

Jun Lu, Wei Xu, Jie Qian, 2019, BMC Medical Genomics.

Interstitial lung abnormalities: What do we know and how do we manage?

K. Chung, B. Han, Feng Li, 2021, Expert review of respiratory medicine.

The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial.

Ying Cheng, B. Han, K. Nan, 2019, Translational lung cancer research.

[Epidermal growth factor receptor gene mutations, amplification and clinicopathologic correlation in patients with lung cancer].

B. Han, Jie Zhang, Hui-quan Gao, 2011, Zhonghua bing li xue za zhi = Chinese journal of pathology.

Epithelial neoplasia coincides with exacerbated injury and fibrotic response in the lungs of Gprc5a-knockout mice following silica exposure

B. Han, B. Zhou, Jiong Deng, 2015, OncoTarget.

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

B. Han, S. Novello, N. Normanno, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han, G. Jiang, H. Pan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma

B. Han, Liyan Jiang, Zhi-qiang Gao, 2020, Translational lung cancer research.

Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer.

B. Han, H. Zhong, Y. Lou, 2020, Annals of palliative medicine.

Feasibility of surgical resection after induction EGFR-TKI therapy for N2 lung adenocarcinomas.

B. Han, L. Xiong, Rong Li, 2020, The Annals of thoracic surgery.

The evaluation of efficacy and safety of sunitinib on EGFR‐TKI pretreated advanced non‐small cell lung cancer patients in China

B. Han, Wei Zhu, Jiaqi Huang, 2014, The clinical respiratory journal.

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

R. Govindan, K. O'Byrne, P. Postmus, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Origin and pharmacological modulation of tumor‐associated regulatory dendritic cells

B. Han, G. Shurin, M. Shurin, 2014, International journal of cancer.

Sonographic Features of Endobronchial Ultrasound in Differentiation of Benign Lymph Nodes.

Lei Wang, B. Han, Jiayuan Sun, 2016, Ultrasound in medicine & biology.

[Comparative study on gemcitabine plus cisplatin and vinorelbine plus ifosfamide plus cisplatin combined chemotherapy in the treatment of advanced non-small cell lung cancer].

B. Han, M. Liao, Yurong Chen, 2004, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[The biologic characteristics and treatment of non-small cell lung cancer in non smokers.].

B. Han, R. Qiao, 2009, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Predicting malignancy of pulmonary ground-glass nodules and their invasiveness by random forest.

Xiaodan Ye, Timothy Deyer, Jingyi Zeng, 2018, Journal of thoracic disease.

Navigation Bronchoscopy-Guided Radiofrequency Ablation for Nonsurgical Peripheral Pulmonary Tumors

B. Han, F. Herth, Jiayuan Sun, 2017, Respiration.

Association of POLK Polymorphisms with Platinum-Based Chemotherapy Response and Severe Toxicity in Non-small Cell Lung Cancer Patients

B. Han, D. Lu, Bo Jin, 2014, Cell Biochemistry and Biophysics.

Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy

B. Han, Bo Jin, Y. Lou, 2016, OncoTargets and therapy.

Genome-Wide Association Study of Prognosis in Advanced Non–Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy

Hongbing Shen, Yi Wang, Chen Wu, 2012, Clinical Cancer Research.

Clinical analysis of Gefitinib in the treatment of stage IV lung adenocarcinoma with unknown EGFR gene mutations

B. Han, L. Xiong, Rong Li, 2013, Thoracic cancer.

[Efficient generation and functional characteristics of dendritic cells from malignant pleural effusion in patients with lung cancer].

B. Han, H. Zhong, Q. Dong, 2004, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

B. Han, B. Lam, D. Garfield, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Design of a prospective, multicenter, and cohort study of an innovative electromagnetic navigation bronchoscopy in diagnosing pulmonary nodules among Chinese population.

B. Han, Jiayuan Sun, Liming Cao, 2019, Journal of thoracic disease.

[Comparison of the Clinical Effects of Paclitaxel and Paclitaxel plus Oxaliplatin as the Second-line Treatment of Advanced Non-small Cell Lung Cancer.].

B. Han, Jie Shen, T. Chu, 2009, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

超声支气管镜引导下的经支气管针吸活检对肺癌的诊断价值

B. Han, Jiayuan Sun, Jie Shen, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.